- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Eflornithine Plus Lomustine Extends PFS, OS in Reclassified WHO Grade 3 IDH-Mutated Astrocytoma
November 23rd 2025, 2:06am
Society for Neuro-Oncology Annual Meeting
Eflornithine plus lomustine produced superior OS and PFS outcomes vs lomustine in WHO grade 3 IDH-mutated astrocytoma.
Temozolomide Plus Radiotherapy Yields Survival Benefit in IDH-Mutant LGG
November 23rd 2025, 1:24am
Society for Neuro-Oncology Annual Meeting
Temozolomide plus radiotherapy significantly improved OS vs radiotherapy alone in IDH-mutant low-grade gliomas without codeletions of 1q and 19q.
Dr de la Fuente on Safety Data With Vorasidenib Plus Temozolomide in IDH-Mutant Glioma
November 23rd 2025, 12:52am
Society for Neuro-Oncology Annual Meeting
Macarena de la Fuente, MD, discusses safety data from the phase 1b IDHEAL-4U trial evaluating vorasidenib plus temozolomide in IDH-mutant glioma.
Dr Kurz on the Efficacy and Safety of Lutetium Lu 177 Dotatate in Advanced Intracranial Meningioma
November 22nd 2025, 10:15pm
Society for Neuro-Oncology Annual Meeting
Sylvia C. Kurz, MD, PhD, discusses the ongoing investigation of the SSTR2-targeting agent 177Lu-DOTATATE in advanced intracranial meningioma.
Mirdametinib Shows Improved ORR Over Time in NF1-Associated Symptomatic Plexiform Neurofibroma
November 22nd 2025, 9:05pm
Society for Neuro-Oncology Annual Meeting
Long-term ReNeu results showed deeper, more durable responses to mirdametinib in NF1-PN with extended treatment in both adults and children.
CAR T-Cell Therapy Shows Early Safety in Recurrent Brain/Leptomeningeal Mets From HER2+ Breast Cancer
November 22nd 2025, 8:18pm
Society for Neuro-Oncology Annual Meeting
HER2-directed CAR T-cell therapy was safe in patients with brain/leptomeningeal metastases from HER2-positive breast cancer.
Dr Lombardi on Phase 1 Data With Regorafenib Plus Temozolomide and CRT for Newly Diagnosed Glioblastoma
November 22nd 2025, 2:56pm
Society for Neuro-Oncology Annual Meeting
Giuseppe Lombardi, MD, PhD, discusses data with regorafenib plus temozolomide and radiation in newly diagnosed, MGMT-methylated, IDH-wild-type glioblastoma.
B7-H3–Directed CAR T-Cell Therapy Has Acceptable Safety Profile in Recurrent Glioblastoma
November 22nd 2025, 4:28am
Society for Neuro-Oncology Annual Meeting
B7-H3–directed CAR T-cell therapy given intraventricularly was well tolerated and showed early efficacy signals in patients with recurrent glioblastoma.
Dr Hirbe on Long-Term Efficacy and Safety Outcomes With Mirdametinib in Symptomatic NF1-PN
November 22nd 2025, 3:10am
Society for Neuro-Oncology Annual Meeting
Angela C. Hirbe, MD, PhD, discusses long-term follow-up data from the phase 2b ReNeu trial evaluating mirdametinib in patients with NF1-associated symptomatic PN.
Mirdametinib Generates Responses and Is Safe in Pediatric Low-Grade Glioma
November 22nd 2025, 2:24am
Society for Neuro-Oncology Annual Meeting
Mirdametinib had clinical activity and was deemed well tolerated in MEK inhibitor–naive pediatric patients with recurrent/progressive low-grade glioma.
Regorafenib Plus Temozolomide and RT Shows Early Signs of Tolerability in MGMT-Methylated, IDH Wild-Type Glioblastoma
November 22nd 2025, 1:50am
Society for Neuro-Oncology Annual Meeting
The RP2D of regorafenib when given with temozolomide and radiotherapy in patients with MGMT-methylated, IDH wild-type glioblastoma was 120 mg.
Vorasidenib Plus Temozolomide Demonstrates Safety in IDH1/2+ Glioma
November 22nd 2025, 1:31am
Society for Neuro-Oncology Annual Meeting
Vorasidenib plus temozolomide was safe in glioma harboring IDH1/2 mutations.
Mecbotamab Vedotin Shows Potential to Extend Survival in Treatment-Refractory Soft Tissue Sarcomas
November 20th 2025, 2:00pm
Mecbotamab vedotin showed promising survival gains and manageable safety in treatment-refractory soft tissue sarcomas.
Genomic, Immune, Epigenetic Features Drive Treatment Decision-Making in High-Risk NSCLC Subtypes
November 19th 2025, 1:04pm
PER® New York Lung Cancer Symposium
Benjamin Herzberg, MD discusses challenges and evolving strategies for managing high-risk NSCLC subsets, underscoring the value of genomic testing.
Dr Herzberg on Management Challenges in STK11/KEAP1+, SMARCA4-Deficient Undifferentiated Tumors and NUT Carcinoma
November 18th 2025, 9:04pm
PER® New York Lung Cancer Symposium
Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.
Newer Generations, Resistance Profiling, and Toxicity Trade-offs Guide Modern TKI Selection/Use in Oncogene-Driven NSCLC
November 18th 2025, 3:00pm
PER® New York Lung Cancer Symposium
Alexander Drilon, MD, summarized approaches to TKI selection in NSCLC displaying oncogenic driver alterations for both TKI-pretreated and -naive patient populations.
Targeted Strategies Push the Envelope for BRAF V600E–, MET Exon 14–, and KRAS G12C–Mutated Metastatic NSCLC
November 17th 2025, 7:28pm
PER® New York Lung Cancer Symposium
Gregory J. Riely, MD, PhD, discusses targeted approaches for BRAF V600E, MET exon 14, and KRAS G12C mutations in metastatic NSCLC.
Advances With Checkpoint Inhibitors, T-Cell Engagers, and ADCs Converge to Reshape the SCLC Treatment Paradigm
November 16th 2025, 11:00am
PER® New York Lung Cancer Symposium
Charles M. Rudin, MD, PhD, discussed evolving standards of care and emerging therapeutics of interest in the SCLC treatment paradigm.
Beyond the Genome: Exploring New Frontiers in NSCLC Management
November 15th 2025, 10:25pm
PER® New York Lung Cancer Symposium
Soo-Ryum (Stewart) Yang, MD, discusses biomarkers for ADCs, the actionability of tumor suppressor genes, and the advent of computational pathology.
Additional Biomarkers Are Needed to Inform ADC Selection in NSCLC
November 15th 2025, 10:11pm
PER® New York Lung Cancer Symposium
Benjamin P. Levy, MD, discusses advances with ADCs in lung cancer during the 20th Annual New York Lung Cancers Symposium.